Skip to main content

Join experts in PNH for a conversation about FABHALTA, an FDA-approved treatment for adults with PNH, regardless of prior complement inhibitor treatment1

Register for a program to:  
 

  • Understand the ongoing challenges for patients with PNH and the evolution of management
  • Dive into the efficacy and safety data for FABHALTA in both C5i-experienced and complement inhibitor–naive adults with PNH
  • Hear perspectives on patients who may be appropriate for FABHALTA
  • Learn about the process for getting patients started
Start adult patients on FABHALTA

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

  • Complete or update vaccinations for encapsulated bacteria at least 2 weeks prior to the first dose of FABHALTA, unless the risks of delaying therapy with FABHALTA outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.

  • Patients receiving FABHALTA are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.

Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.

INDICATION

FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

CLICK OR SCROLL TO SEE IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING AND INDICATION

Definition 
PNH, paroxysmal nocturnal hemoglobinuria.

Reference
1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.